NCT07878364Recruiting
Treatment Patterns and Survival Outcomes in High-Grade Osteosarcoma: A Multicenter Retrospective Study
A Multicenter Medical-Record-Based Retrospective Study of Treatment Patterns and Survival Outcomes in Patients With High-Grade Osteosarcoma
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
This is a multicenter, medical-record-based, retrospective observational study of approximately 400 patients with high-grade osteosarcoma treated at four sites in the Republic of Korea. The study describes treatment patterns and survival outcomes (event-free survival \[EFS\], progression-free survival \[PFS\], and overall survival \[OS\]) in patients who completed or discontinued first-line treatment for high-grade osteosarcoma, irrespective of complete remission status. The primary objective is to retrospectively estimate the 12-month EFS rate, calculated from the date of diagnosis, in the full cohort of high-grade osteosarcoma patients. Key secondary objectives evaluate EFS and OS from the date of confirmed complete remission/no evidence of disease (CR/NED) in the subset of clinically high-risk patients who achieve CR/NED, in order to establish a historical reference data supporting the design and interpretation of a future prospective clinical trial of vactosertib as maintenance therapy.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 400 (estimated)
- First submitted
- 6 Oct 2026
- Start date
- 13 Jul 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- MedPacto, Inc.
- Diseases
- Childhood cancers, Sarcoma
- NCT number
- NCT07878364
What you commit to
- Study type: Observational
- Planned participants: 400
- From 13 Jul 2026 to the primary completion date, 31 Dec 2026
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of a malignancy other than primary osteosarcoma, unless clinically insignificant and fully treated prior to osteosarcoma diagnosis with no investigator-judged impact on osteosarcoma treatment course or survival analysis.
Other
- Primary tumor of soft-tissue origin rather than bone, confirmed pathologically.
- Core data required for survival analysis cannot be verified.
- Transferred to another institution with no available follow-up information, where neither event occurrence, last follow-up date, nor survival status can be determined from pre-transfer records.
- Investigator-judged data errors or inconsistencies
Who the study is looking for
- Pathologically diagnosed high-grade osteosarcoma; age ≥12 years.
- First-line treatment for high-grade osteosarcoma completed or ended at the study institution on or before 2021-06-30.
- Core data required for survival endpoint assessment (EFS, PFS, OS) are available, with at least one of the following satisfied: (a) at least 12 months of follow-up from the date of diagnosis; or (b) an event (relapse, metastasis, disease progression, or death from any cause) confirmed within 12 months of diagnosis.
Age in the registry: 12 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Cancer Center Coordinator of this site? Confirm its status | Goyang-si | South Korea | Recruiting |
| Asan Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Not yet recruiting |
| Korea Cancer Center Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
| Seoul National University Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.